Cancer-related hypercalcemia and potential treatments

Basit Öğe Kaydı
dc.authoridALMURADOVA, ELVİNA/0000-0002-5551-7731
dc.authorwosidALMURADOVA, ELVİNA/IAR-8895-2023
dc.contributor.authorAlmuradova, Elvina
dc.contributor.authorCicin, Irfan
dc.date.accessioned2024-06-12T10:55:34Z
dc.date.available2024-06-12T10:55:34Z
dc.date.issued2023
dc.departmentTrakya Üniversitesien_US
dc.description.abstractCancer-related hypercalcemia is a common finding typically seen in patients with advanced cancer and occurs in about 20 to 30 percent of cases. The most common cause of hypercalcemia in hospitalized patients is hypercalcemia due to malignancy.This clinical problem is seen in patients with both solid tumors and patients with hematologic malignancies. Hypercalcemia is associated with a poor prognosis in oncology patients. This pathologic condition can occur due to many different mechanisms but is usually caused by abnormal calcium use resulting from bone resorption, intestinal absorption, or renal excretion. Hypercalcemia may present with a wide range of symptoms ranging from gastrointestinal system symptoms to neurologic symptoms. Timely diagnosis and initiation of treatment by the physician significantly reduce the risk of complications. Treatment aims to decrease serum calcium by increasing calciuresis, decreasing bone resorption, and decreasing intestinal calcium absorption. The mainstays of treatment are IV hydration, bisphosphonates and calcitonin, denosumab, and in some patients, prednisone, and cinacalcet. Patients with underlying advanced kidney disease and refractory severe hypercalcemia should be evaluated for hemodialysis. Every physician dealing with oncology patients should know the fastest and most effective management of hypercalcemia. We aimed to contribute in this sense.en_US
dc.identifier.doi10.3389/fendo.2023.1039490
dc.identifier.issn1664-2392
dc.identifier.pmid37033238en_US
dc.identifier.scopus2-s2.0-85152547245en_US
dc.identifier.scopusqualityQ1en_US
dc.identifier.urihttps://doi.org/10.3389/fendo.2023.1039490
dc.identifier.urihttps://hdl.handle.net/20.500.14551/19476
dc.identifier.volume14en_US
dc.identifier.wosWOS:000963049700001en_US
dc.identifier.wosqualityN/Aen_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherFrontiers Media Saen_US
dc.relation.ispartofFrontiers In Endocrinologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectCanceren_US
dc.subjectHypercalcaemiaen_US
dc.subjectTreatmenten_US
dc.subjectMaligancyen_US
dc.subjectTherapyen_US
dc.subjectHormone-Related Proteinen_US
dc.subjectReversible Encephalopathy Syndromeen_US
dc.subjectParathyroid-Hormoneen_US
dc.subjectGallium Nitrateen_US
dc.subjectMultiple-Myelomaen_US
dc.subjectPrimary Hyperparathyroidismen_US
dc.subjectContaining Bisphosphonatesen_US
dc.subjectMalignant Hypercalcemiaen_US
dc.subjectHumoral Hypercalcemiaen_US
dc.subjectReceptor Activatoren_US
dc.titleCancer-related hypercalcemia and potential treatmentsen_US
dc.typeReview Articleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu